Investigating the Role of Anti- Angiogenic Agents in Ovarian Cancer Carol Aghajanian, M.D. Chief, Gynecologic Medical Oncology Memorial Sloan-Kettering.

Slides:



Advertisements
Similar presentations
“Taking Care of Tomorrows Patient Better than Today”… the Future is Now Set A1 – Title Slide David O’Malley, M.D.
Advertisements

Gynecologic Oncology Group Gynecologic Oncology Group Uterine Corpus Trials: GCIG David Scott Miller, M.D., F.A.C.O.G., F.A.C.S. Director and Dallas Foundation.
O VARIAN C ANCER C LINICAL T RIALS P LANNING M EETING Unanswered Questions in Upfront Therapy IP Therapy Issue Keiichi Fujiwara, MD, PhD Saitama Medical.
Ana Oaknin, MD Medical Oncology Department. Gyneacological Cancer Unit
Randomized Phase III Trials of Intravenous vs. Intraperitoneal Therapy in Optimal Ovarian Cancer Deborah K. Armstrong, M.D. Associate Professor of Oncology,
‍‍‍‍Chemotherapy in epithelial ovarian cancer. Dr.Azarm.
Memorial Sloan-Kettering Cancer Center
Fabio Puglisi Dipartimento di Oncologia Azienda Ospedaliero Universitaria di Udine Antiangiogenic Treatment Mediterranean School of Oncology.
Unanswered Questions in Primary Treatment of Ovarian Cancer: Controversial Areas Deborah K. Armstrong, M.D. May 29, 2009.
Academic & Community Cancer Research United (ACCRU) Scientific Achievements.
Evidence Based Decision Making In Gynecologic Cancer Paolo Zola Turin, ITALY Adriana Bermudez Buenos Aires, ARGENTINA.
A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)
AVADO PFS Analysis (ITT Population) All P values vs. placebo Adapted from Miles et al. ASCO 2008, abstract LBA 1011.
GCIG Meeting 29th May 2009 The Implications of Primary Chemotherapy for Clinical Trials Iain McNeish Professor of Gynaecological Oncology Barts and the.
Phase III Trial of Bevacizumab in the Primary Treatment of Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer: A Gynecologic Oncology.
First-Line TKI Use in EGFR Mutation-Positive NSCLC
Ovarian Cancer Dr Helen Mackay.
Copyright © 2010, Research To Practice, All rights reserved. Part II: Ovarian Cancer Monday, September 27, :30 PM - 8:30 PM ET Monday Night with.
Nab-paclitaxel Development in Gynecologic Malignancies Robert Coleman, MD, FACOG, FACS Director of Clinical Research Department of Gynecologic Oncology.
LUNG CANCER: ASCO 2006 TOPICS Adjuvant therapy Clinical studies Meta-analysis ChemoXRT for stage III disease Advances in stage IV NSCLC New agents Predictive.
Treatment of Refractory Ovarian Cancer
Cancer Center Stanford University Gynecologic Cancer Treatment ASCO 2006 Update: Gynecologic Cancers Amreen Husain, M.D. Assistant Professor Division of.
Are there benefits from chemotherapy to early endometrial cancer
Partnering with Industry Katherine Y. Look M.D. Medical Fellow I Eli Lilly NCI/GCIG Panel Discussion May 29, 2009.
Use of Chemotherapeutic and Biologic Agents in Metastatic Breast Cancer Breast Cancer Update Medical Oncology Educational Forum May 21, 2005 Kathy D Miller.
Be it resolved that… IP therapy should be the standard of care for women with optimally debulked Stage III ovarian cancer Not so fast… Michael A Bookman.
Result of Interim Analysis of Overall Survival in the GCIG ICON7 Phase III Randomized Trial of Bevacizumab in Women with Newly Diagnosed Ovarian Cancer.
Assistant Professor of Medicine Dana-Farber Cancer Institute
Targeting VEGF for the Treatment of Colorectal Cancer Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA.
Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma Sternberg CN et al. ASCO 2009; Abstract (Oral Presentation)
Clique para editar o título mestre. Incorporation of bevacizumab in first-line treatment of advanced ovarian cancer: results and indications Ursula Matulonis,
1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.
GOG0172: The Dings The recommended regimen is not feasible –Substitution of carboplatin for cisplatin –Reduce cisplatin from 100 mg/m 2 to 75 mg/m 2 –Change.
Gemcitabine + Cisplatin +/- Bevacizumab as 1st-line Treatment of Advanced NSCLC: AVAiL Study Manegold PASCO 25:#7514, 2007/Ann.
Chemotherapy in advanced ovarian cancer Angiolo Gadducci Department of Gynecology and Obstetrics, Unit of Gynecologic Oncology, University of Pisa Rome.
WHAT WILL THE KEY ISSUES IN END- POINT ASSESSMENT BE, IN FUTURE OVARIAN CANCER TRIALS INVOLVING NOVEL TARGETED AGENTS? first line treatment maintenance/consolidation.
E2100 A Randomized Phase III Trial of Paclitaxel versus Paclitaxel plus Bevacizumab as First- Line Therapy for Locally Recurrent or Metastatic Breast Cancer.
GCIG Rare Tumor Working Group Chicago, IL, June 3, 2010 Chair: Isabelle Ray-Coquard Co-Chair: David M. Gershenson.
Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.
AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.
OCEANS: A Randomized, Double- Blinded, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab (BEV) in Patients with Platinum-
Kang Y et al. Proc ASCO 2010;Abstract LBA4007.
A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.
CALYPSO Trial: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum- Sensitive Ovarian Cancer Pujade-Lauraine.
A Discussion on Biologic Agents in Gastric Cancer Treatment Yoon-Koo Kang, MD Professor of Medicine Asan Medical Center University of Ulsan College of.
Personalized therapy in ovarian cancer Dragos Median “Filantropia” Clinical Hospital, Bucharest.
GCIG trials for rare ovarian histologies Edward L. Trimble, MD, MPH National Cancer Institute, USA.
ENDOMETRIAL CARCINOMA UPDATES Dr Marco Matos Gold Coast Cancer Care, Gold Coast University Hospital and Pacific Private Oncology Group.
MITO 25 A randomized phase II trial of Carboplatin-Paclitaxel- Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab- Rucaparib vs Carboplatin-Paclitaxel-Rucaparib.
Pazopanib in Advanced Ovarian Cancer: A new galloping horse. Dr. Raafat Ragaie, MD,FRCR.
Relapsed/Refractory Ovarian Cancer: Decision Points in Diagnosis and New Treatment Strategies Friday, March 24, 2006 Palm Springs Convention Center Primrose.
MITO 25 A randomized phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib.
Saturday, May 30, :00 PM - 9:00 PM The Peabody Orlando Orlando, Florida Ovarian Cancer: Recent Developments in the Standard of Care and Emerging.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 GOG0213: Bevacizumab Retreatment of Recurrent Platinum-Sensitive Ovarian.
Phase I/II CheckMate 032: Nivolumab ± Ipilimumab in Advanced SCLC
Case Discussion: Second Opinion
Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)
Ovarian cancer update Kentucky cancer Registry 9/8/2016
Management of metastatic and recurrent head and neck cancer
Farletuzumab in platinum sensitive ovarian cancer with low CA125
What do we do after FOLFIRINOX? Gemcitabine-Based Therapy is Standard
A Phase Ib Study of CRLX101 in Combination with Weekly Paclitaxel in Platinum-Resistant Ovarian Cancer Adrian Senderowicz, MD 19 May 2016.
Bevacizumab in platinum-sensitive ovarian cancer: OCEANS.
Barrios C et al. SABCS 2009;Abstract 46.
Baselga J et al. SABCS 2009;Abstract 45.
Nab-paclitaxel in Ovarian Cancer
PARP Inhibitors.
MAINTENANCE THERAPY WITH PARP INHIBITORS
Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.
Joan L. Walker, M.D. Stephenson Cancer Center University of Oklahoma
Presentation transcript:

Investigating the Role of Anti- Angiogenic Agents in Ovarian Cancer Carol Aghajanian, M.D. Chief, Gynecologic Medical Oncology Memorial Sloan-Kettering Cancer Center

Phase III: GOG 218 Stage III* or IV, Ovarian, primary peritoneal, or fallopian tube cancer Activated: 9/26/05 Activated: 9/26/05 Accrual goal: 1800 pts Accrual goal: 1800 pts Primary end point: PFS Primary end point: PFS Carboplatin/Paclitaxel - cycles 1-6 Concurrent Placebo - cycles 2-6 Placebo - cycles 7-22 Carboplatin/Paclitaxel – cycles 1-6 Concurrent Bevacizumab – cycles 2-6 Placebo – cycles 7-22 Carboplatin/Paclitaxel – cycles 1-6 Concurrent Bevacizumab – cycles 2-6 Bevacizumab – cycles 7-22 *optimal (gross residual) or suboptimal

Phase III: ICON7 Carboplatin: AUC6; Paclitaxel 175mg/m 2 Cycles: 21 days High risk early stage/Advanced stage Ovarian, primary peritoneal, or fallopian tube cancer Carboplatin/Paclitaxel x 6 cycles Observation Bevacizumab 7.5 mg/kg x 5-6 cycles Bevacizumab 7.5 mg/kg x 12 cycles Target Accrual: 1520 Primary endpoint: PFS

IP Therapy: Randomized Trials IV ARMIP ARMP value GOG 104 IV cyclophosphamide + IV or IP CDDP OS41 mos49 mos0.02 GOG 114 IV Pac + IV CDDP or IV carbo then IV Pac + IP CDDP PFS22 mos28 mos0.01 OS52 mos63 mos0.05 GOG 172 IV Pac + IV CDDP or IV/IP Pac + IP CDDP PFS18.3 mos23.8 mos0.05 OS49.7 mos65.6 mos0.03 Alberts et al. NEJM 1996, Markman et al. JCO 2001, Armstrong et al. NEJM 2006

Modulating Toxicity of IP Therapy New approaches to improve toxicity profile while maintaining efficacy –Dose/schedule modifications –Docetaxel instead of paclitaxel –IP Carboplatin instead of IP cisplatin –The role of bevacizumab

IP Chemotherapy: Modification GOG 172 Modified D1: IV Paclitaxel (135 mg/m 2 /24h) D2: IP Cisplatin (100 mg/m 2 ) D8: IP Paclitaxel (60 mg/m 2 ) D1: IV Paclitaxel (135 mg/m 2 /3h) D2: IP Cisplatin (75 mg/m 2 ) D8: IP Paclitaxel (60 mg/m 2 ) D1 IV D2 IP D1 IV D2 IP D8 IP D8 IP

Phase I - GOG Part A 9916 Part C D1: IV Paclitaxel (175 mg/m 2 /3h) D1: IP Carboplatin (AUC 6) D8: IP Paclitaxel (60 mg/m 2 ) D1: IV Paclitaxel (175 mg/m 2 /3h) D1: IP Carboplatin (AUC 6) D1: IV Bevacizumab (15 mg/kg)* D8: IP Paclitaxel (60 mg/m 2 ) D1 IV D1 IP D1 IV D1 IP D8 IP D8 IP 9916 Part B D1 IV D1 IP D8 IP D1: IV Docetaxel (75 mg/m 2 /1h) D1: IP Carboplatin (AUC 6) D8: IP Paclitaxel (60 mg/m 2 ) *beginning cycle 2, day 1 and continuing for 17 total cycles

Phase I - GOG Part A D1: IV Paclitaxel (175 mg/m 2 /3h) D1: IP Carboplatin (AUC 6) D1 IV D1 IP D8 IP 9917 Part B D1 IV D1 IP D8 IP D1: IV Paclitaxel (175 mg/m2/3h) D1: IP Carboplatin (AUC 6) D1: IV Bevacizumab 15 mg/kg* *beginning cycle 2, day 1 and continuing for 17 total cycles

MSKCC Modified GOG D1: IV Paclitaxel (135 mg/m 2 /3h) D2: IP Cisplatin (75 mg/m 2 ) D8: IP Paclitaxel (60 mg/m 2 ) D1: IV Paclitaxel (135 mg/m 2 /3h) D1: IV Bevacizumab (15 mg/kg)* D2: IP Cisplatin (75 mg/m 2 ) D8: IP Paclitaxel (60 mg/m 2 ) D1 IV D2 IP D1 IV D2 IP D8 IP D8 IP *beginning cycle 2, day 1 and continuing through cycle 22 PI: Dr. Jason Konner

ASCO 2008: Phase III IV paclitaxel and carboplatin vs. dose dense (TC-T-T) JGOG: 637 patients randomized, Stage III diagnosis TC vs TC-T-T (80 mg/m 2 ) weekly Primary endpoint PFS –0.8 power to detect 5 month difference TreatmentNMedian PFS P valueHR95% CI TC mos TC-T- T mos year OS TC % TC-T-T % Isonishi et al. J Clin Oncol 26: 2008, abs 5506

Phase III: GOG 0252 Stage II or III (<1cm residual), Ovarian, primary peritoneal, or fallopian tube cancer Accrual goal: 1100 pts Accrual goal: 1100 pts Primary end point: PFS Primary end point: PFS Paclitaxel 80 mg/m 2 /1h IV, Days 1, 8, 15, Cycles 1-6 Carboplatin AUC 6 IV, Day 1, Cycles 1-6 Bevacizumab 15 mg/kg IV, Cycles 2-22 Paclitaxel 80 mg/m 2 /1h IV, Days 1, 8, 15, Cycles 1-6 Carboplatin AUC 6 IP, Day 1, Cycles 1-6 Bevacizumab 15 mg/kg IV, Cycles 2-22 Paclitaxel 135 mg/m 2 /3h IV, Day 1, Cycles 1-6 Cisplatin 75 mg/m 2 IP, Day 2, Cycles 1-6 Paclitaxel 60 mg/m 2 IP, Day 8, Cycles 1-6 Bevacizumab 15 mg/kg IV, Cycles 2-22 RANDOMIZERANDOMIZE

Relapse Therapy: Past Primary treatment RELAPSE < 6 months> 6 months Platinum ResistantPlatinum Sensitive

Bevacizumab in Recurrent Ovarian Cancer StudyNTreatmentRR (%) PF 6 mo (%) Prior RxGIP GOG 170-D 1 62BV 15 mg/kg IV q 3 wk % platinum resistant, 1-2 priors 0 NCI BV 10 mg/kg IV q 2 wk + CTX 50 mg daily % platinum resistant, 1-3 priors 4 (5.7%) AVF BV 15 mg/kg IV q 3 wk Platinum resistant, 1-3 priors 5 (11%) 1 Burger et al. JCO 2007, 2 Garcia et al. JCO 2008, 3 Cannistra et al. JCO 2007

AVF2949g: Risk Factors for GI Perforation Cannistra, et al JCO 2007 P <0.1 P < 0.05 Radiographic Prior Treatment

Single Agent Activity of Bevacizumab Tumor TypeDoseORR (PR+CR) Ovarian Cancer15mg/kg q3wk16-21% Renal Cell10mg/kg q2wk10% Met Breast Cancer 3-20mg/kg q2wk7% NHL10mg/kg q2wk5% CRC10mg/kg q2wk3% HRPC10mg/kg q2wk0%

Ovarian Cancer: Biologics STUDYAGENTNRR (%)PFS at 6 months (%) 170-CGefitinib DBevacizumab EImatinib FSorafenib GLapatinib HVorinostat ITemsirolimusBoth stages of accrual completed 170-JEnzastaurin KMifepristoneClosed after first stage 170-MDasatinibFirst stage accrual completed

ASCO 2008 Agent/ Abstract No. NRR (%)PFSPrior RX Sorafenib (5537) (2/59)23.7% PF at 6 mo 1-2 priors Cediranib (5501) (6/32)-1-3 priors Cediranib (5521) (2/26) – Pl-S 0 – Pl-R -1-2 priors Sunitinib (5522) (2/17)-1-2 priors

VEGF-TRAP VEGF Trap 2 mg/kg IV q 2 weeks VEGF Trap 4 mg/kg IV q 2 weeks Recurrent ovarian cancer lines treatment Platinum-resistant Resistant: Topotecan and/or Liposomal Doxorubicin Randomized (1:1) Double-Blinded N = 200 Tew et al. ASCO 2007 Primary endpoint: RR Preliminary results: 8% (blinded pooled summary of first 162 patients) 50% of patients with 4 prior chemotherapy regimens

Recurrent Disease: Platinum Sensitive ICON4 1 AGO 2 1 ICON4 Lancet 2003 and 2 Pfisterer et al JCO 2006

RANDOMIZATIONRANDOMIZATIONRANDOMIZATIONRANDOMIZATION Gemcitabine 1000 mg/m² days 1 and 8 Carboplatin AUC 4 day 1 Bevacizumab 15 mg/kg day 1 q 21 days x 6 Gemcitabine 1000 mg/m² days 1 and 8 Carboplatin AUC 4 day 1 Placebo IV day 1 q 21 days x 6 OCEANS STUDY –PHASE III Bevacizumab until PD Placebo *Up to 10 cycles of gemcitabine/carboplatin allowed

OCEANS STUDY Recurrent Ovarian Cancer Recurrent Ovarian Cancer > 6 months off platinum > 6 months off platinum Measurable disease Measurable disease Strata: Strata: – Platinum-free interval (>6-12, > 12 months) – Cytoreductive surgery for recurrent ovarian cancer (yes/no) Primary Objective Primary Objective –PFS (Investigator determined) – HR 0.73 Sample size Sample size –450 pts

PaclitaxelCarboplatinBevacizumabPaclitaxelCarboplatin GOG 213 –PHASE III MaintenanceBevacizumab Surgical Candidate? Randomize No Yes Randomize Surgery No Surgery Primary endpoint: OS Target accrual: 660

ICON6 First platinum- sensitive recurrence Ovarian, primary peritoneal, or fallopian tube cancer Carboplatin/Paclitaxel* x 6 cycles Concurrent Placebo Maintenance Placebo Carboplatin/Paclitaxel* x 6 cycles Concurrent Cediranib Maintenance Placebo Carboplatin/Paclitaxel* x 6 cycles Concurrent Cediranib Maintenance Cediranib *Carboplatin alone is allowed

Future Directions Combinations –GOG 186G: Randomized Phase II study of bevacizumab/everolimus vs. bevacizumab/placebo Novel Agents

Selected Combinations in Trials TargetsClinical trialsTumor types VEGF + VEGFR BV + SorafenibRCC, Ovarian, Melanoma BV + CederanibPhase I BV + SunitinibRCC VEGF + mTORBV + CCI-779*RCC, Ovary, Endometrial, HCC, NEC Sorafenib + CCI-779RCC, Melanoma, GBM VEGF + PDGFBV + Imatinib*Melanoma, GIST, RCC VEGFR + IntegrinBV + Medi-552RCC BV + CilengitideGBM Angio + Tumor targetsVEGF Ab or TKIs + EGFR, HER2, HDAC inhibitors, Immunotherapy, etc

Combination of anti-angiogenesis agents – preliminary toxicity data (Phase I experience) MTDToxicities CCI SunitinibNot tolerable (15 mg + 25 mg) DLT: Mucocutaneous (no further development) CCI SorafenibDose reduction (for one agent) DLT: Mucocutaneous, Plts  BV + SorafenibDose reduction (both agents: 50%  ) DLT: HUS, HTN, proteinuria SAEs: GI perf, fistula, bleeding BV + SunitinibNot Tolerability at full doses in RCC SAEs: HUS/TTP-like syndrome HTN BV + CCI-779Full doseNonspecific Exposures in more pts and for longer duration may reveal additional serious toxicities that are relatively low-frequency

Conclusions Angiogenesis is an important target in Ovarian Cancer Initial treatment –GOG 218 –ICON7 –IP Therapy First Platinum-Sensitive Recurrence –Oceans –GOG 213 –ICON6 Recurrent Disease –Multiple single agent phase II trials Platinum resistant disease –Chemotherapy combinations –“First” platinum resistant recurrence Combinations –Toxicity will limit the number of agents that can be given simultaneously –When dose reduction is required, optimal dose ratio unknown for optimal therapeutic index